Meden H - Search Results

1

The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs.

Fasching PA, von Minckwitz G, Fischer T, Kaufmann M, Schultz-Zehden B, Beck H, Lux MP, Jacobs V, Meden H, Kiechle M, Beckmann MW, Paepke S. Fasching PA, et al. Among authors: meden h. Breast Cancer Res Treat. 2007 Jan;101(1):95-104. doi: 10.1007/s10549-006-9272-2. Epub 2006 Oct 11. Breast Cancer Res Treat. 2007. PMID: 17033928

2

A clinical, mammographic, sonographic and histologic evaluation of breast cancer.

Meden H, Neues KP, Röben-Kämpken S, Kuhn W. Meden H, et al. Int J Gynaecol Obstet. 1995 Feb;48(2):193-9. doi: 10.1016/0020-7292(94)02278-7. Int J Gynaecol Obstet. 1995. PMID: 7789593 Clinical Trial.

3

Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy.

Meden H, Marx D, Fattahi A, Rath W, Kron M, Wuttke W, Schauer A, Kuhn W. Meden H, et al. J Cancer Res Clin Oncol. 1994;120(6):378-81. doi: 10.1007/BF01247465. J Cancer Res Clin Oncol. 1994. PMID: 7908021

4

Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7).

Pradier O, Rave-Fränk M, Schmidberger H, Bömecke M, Lehmann J, Meden H, Hess CF. Pradier O, et al. Among authors: meden h. J Cancer Res Clin Oncol. 1999;125(1):20-7. doi: 10.1007/s004320050237. J Cancer Res Clin Oncol. 1999. PMID: 10037273

5

Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer.

Meden H, Marx D, Schauer A, Wuttke W, Kuhn W. Meden H, et al. Anticancer Res. 1997 Jan-Feb;17(1B):757-60. Anticancer Res. 1997. PMID: 9066616

6

Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum.

Mielke S, Meden H, Raab T, Wuttke W, Kuhn W. Mielke S, et al. Among authors: meden h. Anticancer Res. 1997 Jul-Aug;17(4B):3125-7. Anticancer Res. 1997. PMID: 9329617

7

Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations.

Meden H, Mielke S, Marx D, Wuttke W, Kuhn W. Meden H, et al. Anticancer Res. 1997 Jul-Aug;17(4B):3075-7. Anticancer Res. 1997. PMID: 9329605

8

Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide.

Meden H, Meissner O, Conrad A, Kuhn W. Meden H, et al. Eur J Gynaecol Oncol. 1996;17(2):114-22. Eur J Gynaecol Oncol. 1996. PMID: 8654467 Clinical Trial.

9

EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value.

Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W. Meden H, et al. J Obstet Gynaecol (Tokyo 1995). 1995 Apr;21(2):167-78. doi: 10.1111/j.1447-0756.1995.tb01090.x. J Obstet Gynaecol (Tokyo 1995). 1995. PMID: 8556578

10

Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.

Meden H, Wittkop Y, Kuhn W. Meden H, et al. Anticancer Res. 1997 May-Jun;17(3C):2221-3. Anticancer Res. 1997. PMID: 9216692 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters